Diasome Will Present Phase 2b Diabetes Study Findings
The company will share OPTI-2 trial data at two international medical conferences this autumn.
Updated on Sept. 21, 2026 in Diabetes
Live Poll
Do you generally trust that new medical treatments will be safer than the ones currently available?
Diasome Pharmaceuticals will present findings from its Phase 2b OPTI-2 study starting on September 28, 2026. The data release will provide insights into the performance of its investigational HDV-insulin lispro therapy.
Why it matters
The study aims to determine if HDV-insulin lispro can effectively maintain glycemic control for patients with type 1 diabetes while simultaneously reducing the occurrence of hypoglycemia. These results offer a potential alternative for patients managing insulin-dependent conditions.
The 25-week OPTI-2 trial featured a 12-week dose-optimization period followed by a 13-week dose-maintenance phase. Participants utilized Dexcom G7 continuous glucose monitoring devices to track their glycemic responses.
The players
Diasome Pharmaceuticals
This biotechnology company focuses on developing liver-targeted insulin therapies and metabolic disease treatments.
Dexcom
This medical device company produces continuous glucose monitoring systems used for diabetes management.
Breakthrough T1D
Formerly known as JDRF, this global non-profit organization funds research for type 1 diabetes treatments and cures.
The details
The study evaluated mealtime HDV-insulin lispro administered alongside once-daily insulin degludec. Researchers utilized weekly CGM-guided titration during the optimization period to refine individual dosage requirements for study participants.
Timeline
September 28, 2026: The EASD Annual Meeting commences in Milan, Italy.
October 2, 2026: The OPTI-2 study findings will be presented at the EASD conference.
October 9, 2026: The Breakthrough T1D Clinical & Research Congress begins.
October 10, 2026: New EAIR analyses will be presented in Philadelphia.
The Big Picture
The upcoming presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting marks a critical step in the validation of new insulin delivery methods. This follows a broader industry push to improve glycemic outcomes through technology-integrated dosing.
The results of this study could eventually impact how patients manage blood glucose levels and daily insulin dosing routines. Because HDV-insulin lispro is not yet FDA-approved, the therapy is not currently available for routine clinical treatment.
The takeaway
Patients should continue following current medical guidance and approved insulin regimens while research into new delivery methods proceeds. These results will provide clarity on whether new therapies can safely offer better control of blood sugar levels.
Further reading
For more information on clinical advancements, visit our Diabetes section.
Live Poll
Do you generally trust that new medical treatments will be safer than the ones currently available?
